Publication
Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (15)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 15
- cancerGastric Carcinomacivic_curation1.00
- cancerMalignant Gastric Neoplasmcivic_curation1.00
- drugCisplatincivic_curation1.00
- drugDoxorubicincivic_curation1.00
- drugEAP Protocolcivic_curation1.00
- drugEtoposidecivic_curation1.00
- drugMitomycincivic_curation1.00
- geneTP53civic_curation1.00
- variantTP53 Mutationcivic_curation1.00
- variantTP53 Overexpressioncivic_curation1.00
- variantTP53 R175Hcivic_curation1.00
- variantTP53 R213Pcivic_curation1.00
- variantTP53 R273Ccivic_curation1.00
- variantTP53 R282Lcivic_curation1.00
- variantTP53 Y220Ccivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 14514923
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TP53 Mutation1 | ||||||||
| Cisplatin + Doxorubicin + EtoposideCombination | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID2820In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R175H1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2310In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R213P1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2819In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R273C1 | ||||||||
| Cisplatin + Etoposide + MitomycinCombination | Gastric CarcinomaALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID2292A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R282L1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2818In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 Y220C1 | ||||||||
| Cisplatin + Etoposide + MitomycinCombination | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2306A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 Overexpression1 | ||||||||
| Cisplatin + Etoposide + MitomycinCombination | Malignant Gastric Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID2799In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater t… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |